Meniere’s Disease Treatment Market Research Report Information by Treatment (Drug, Injections, Positive Pressure Therapy, and Surgery), End-User (Hospital and Clinics, Specialty Centers) and Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Forecast till 2030

1 EXECUTIVE SUMMARY

1.1 MARKET SYNOPSIS 15

1.2 MARKET ATTRACTIVENESS ANALYSIS 16

1.3 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT 17

1.4 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, BY END USER 18

2 MARKET INTRODUCTION

2.1 DEFINITION 19

2.2 SCOPE OF THE STUDY 19

2.3 RESEARCH OBJECTIVE 19

2.4 MARKET STRUCTURE 20

2.5 ASSUMPTIONS & LIMITATIONS 20

3 RESEARCH METHODOLOGY

3.1 DATA MINING 21

3.2 SECONDARY RESEARCH 22

3.3 PRIMARY RESEARCH 23

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 24

3.5 FORECASTING TECHNIQUES 24

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 25

3.6.1 BOTTOM-UP APPROACH 26

3.6.2 TOP-DOWN APPROACH 26

3.7 DATA TRIANGULATION 27

3.8 VALIDATION 27

4 MARKET FACTOR ANALYSIS

4.1 PORTER’S FIVE FORCES MODEL 28

4.1.1 THREAT OF NEW ENTRANTS 29

4.1.2 BARGAINING POWER OF SUPPLIERS 29

4.1.3 THREAT OF SUBSTITUTES 29

4.1.4 BARGAINING POWER OF BUYERS 29

4.1.5 INTENSITY OF RIVALRY 29

4.2 VALUE CHAIN ANALYSIS 30

4.2.1 R&D AND DESIGNING 31

4.2.2 MANUFACTURING 31

4.2.3 DISTRIBUTION 31

4.2.4 MARKETING & SALES 31

4.2.5 POST-SALES MONITORING 31

5 MARKET DYNAMICS

5.1 OVERVIEW 32

5.2 DRIVERS 33

5.2.1 HIGH PREVALENCE RATE OF MENIERE’S DISEASE 33

5.2.2 INITIATIVES TO CREATE AWARENESS REGARDING VESTIBULAR DISORDERS IN DEVELOPED COUNTRIES 33

5.2.3 DRIVERS IMPACT ANALYSIS 34

5.3 RESTRAINTS 34

5.3.1 LACK OF AWARENESS REGARDING SYMPTOMS IN DEVELOPING COUNTRIES 34

5.3.2 ADVERSE SIDE EFFECTS OF SYMPTOMATIC TREATMENTS 34

5.3.3 RESTRAINTS IMPACT ANALYSIS 35

5.4 OPPORTUNITIES 35

5.4.1 STRONG PIPELINE FOCUSED ON THE TREATMENT OF MENIERE’S DISEASE 35

6 GLOBAL MENIERE’S DISEASE TREATMENT MARKET BY TREATMENT

6.1 OVERVIEW 36

6.2 DRUGS 38

6.2.1 ANTI VERTIGO DRUGS 38

6.2.2 DIURETICS 38

6.2.3 OTHERS 38

6.3 INJECTIONS 40

6.3.1 STEROIDS INJECTIONS 40

6.3.2 GENTAMICIN INJECTIONS 40

6.4 POSITIVE PRESSURE THERAPY 41

6.5 SURGERY 42

6.5.1 ENDOLYMPHATIC SAC SURGERY 42

6.5.2 VESTIBULAR NERVE SECTION 42

6.5.3 LABYRINTHECTOMY 42

6.5.4 OTHER 42

7 GLOBAL MENIERE’S DISEASE TREATMENT MARKET BY END USER

7.1 OVERVIEW 44

7.2 HOSPITAL AND CLINICS 46

7.3 SPECIALTY CENTERS 47

7.4 OTHERS 47

8 GLOBAL MENIERE’S DISEASE TREATMENT MARKET BY REGION

8.1 OVERVIEW 48

8.2 AMERICAS 50

8.2.1 NORTH AMERICA 54

8.2.1.1 US 58

8.2.1.2 CANADA 61

8.2.2 LATIN AMERICA 64

8.3 EUROPE 68

8.3.1 WESTERN EUROPE 72

8.3.1.1 GERMANY 76

8.3.1.2 UK 79

8.3.1.3 FRANCE 82

8.3.1.4 ITALY 85

8.3.1.5 SPAIN 88

8.3.1.6 REST OF WESTERN EUROPE 91

8.3.2 EASTERN EUROPE 94

8.4 ASIA-PACIFIC 98

8.4.1 JAPAN 102

8.4.2 AUSTRALIA 105

8.4.3 CHINA 108

8.4.4 INDIA 111

8.4.5 SOUTH KOREA 114

8.4.6 REST OF ASIA-PACIFIC 117

8.5 MIDDLE EAST & AFRICA 121

8.5.1 MIDDLE EAST 125

8.5.2 AFRICA 128

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW 132

9.2 COMPETITIVE BENCHMARKING 133

9.3 COMPETITOR DASHBOARD 134

9.4 PIPELINE ANALYSIS 135

10 COMPANY PROFILES

10.1 LINA MEDICAL APS 136

10.1.1 COMPANY OVERVIEW 136

10.1.2 FINANCIAL OVERVIEW 136

10.1.3 PRODUCTS/SERVICES OFFERED 136

10.1.4 KEY DEVELOPMENTS 136

10.1.5 SWOT ANALYSIS 137

10.1.6 KEY STRATEGIES 137

10.2 WALLACE PHARMA 138

10.2.1 COMPANY OVERVIEW 138

10.2.2 FINANCIAL OVERVIEW 138

10.2.3 PRODUCTS/SERVICES OFFERED 138

10.2.4 KEY DEVELOPMENTS 138

10.2.5 SWOT ANALYSIS 139

10.2.6 KEY STRATEGIES 139

10.3 JUBILANT CADISTA 140

10.3.1 COMPANY OVERVIEW 140

10.3.2 FINANCIAL OVERVIEW 141

10.3.3 PRODUCTS/SERVICES OFFERED 141

10.3.4 KEY DEVELOPMENTS 142

10.3.5 SWOT ANALYSIS 142

10.3.6 KEY STRATEGIES 142

10.4 PFIZER INC. 143

10.4.1 COMPANY OVERVIEW 143

10.4.2 FINANCIAL OVERVIEW 144

10.4.3 PRODUCTS/SERVICES OFFERED 144

10.4.4 KEY DEVELOPMENTS 144

10.4.5 SWOT ANALYSIS 145

10.4.6 KEY STRATEGIES 145

10.5 GLENMARK PHARMACEUTICALS 146

10.5.1 COMPANY OVERVIEW 146

10.5.2 FINANCIAL OVERVIEW 147

10.5.3 PRODUCTS/SERVICES OFFERED 147

10.5.4 KEY DEVELOPMENTS 147

10.5.5 SWOT ANALYSIS 148

10.5.6 KEY STRATEGIES 148

10.6 GLAXOSMITHKLINE PLC 149

10.6.1 COMPANY OVERVIEW 149

10.6.2 FINANCIAL OVERVIEW 150

10.6.3 PRODUCTS/SERVICES OFFERED 150

10.6.4 KEY DEVELOPMENTS 150

10.6.5 SWOT ANALYSIS 151

10.6.6 KEY STRATEGIES 151

10.7 WELLSPRING PHARMACEUTICAL CORPORATION 152

10.7.1 COMPANY OVERVIEW 152

10.7.2 FINANCIAL OVERVIEW 152

10.7.3 PRODUCTS/SERVICES OFFERED 152

10.7.4 KEY DEVELOPMENTS 152

10.7.5 SWOT ANALYSIS 153

10.7.6 KEY STRATEGIES 153

10.8 SOUND PHARMACEUTICALS 154

10.8.1 COMPANY OVERVIEW 154

10.8.2 FINANCIAL OVERVIEW 154

10.8.3 PRODUCTS/SERVICES OFFERED 154

10.8.4 KEY DEVELOPMENTS 154

10.8.5 SWOT ANALYSIS 155

10.8.6 KEY STRATEGIES 155

10.9 AURIS MEDICAL 156

10.9.1 COMPANY OVERVIEW 156

10.9.2 FINANCIAL OVERVIEW 156

10.9.3 PRODUCTS/SERVICES OFFERED 156

10.9.4 KEY DEVELOPMENTS 156

10.9.5 SWOT ANALYSIS 157

10.9.6 KEY STRATEGIES 157

10.10 OTONOMY, INC. 158

10.10.1 COMPANY OVERVIEW 158

10.10.2 FINANCIAL OVERVIEW 158

10.10.3 PRODUCTS/SERVICES OFFERED 159

10.10.4 KEY DEVELOPMENTS 159

10.10.5 SWOT ANALYSIS 160

10.10.6 KEY STRATEGIES 160

11 APPENDIX

11.1 REFERENCES 161

11.2 RELATED REPORTS 161

12 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS 20

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 23

TABLE 3 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 37

TABLE 4 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY REGION, 2022–2030 (USD Billion) 38

TABLE 5 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 39

TABLE 6 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 39

TABLE 7 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY REGION, 2022–2030 (USD Billion) 40

TABLE 8 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 41

TABLE 9 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, FOR POSITIVE PRESSURE THERAPY, BY REGION, 2022–2030 (USD Billion) 41

TABLE 10 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY REGION, 2022–2030 (USD Billion) 43

TABLE 11 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 43

TABLE 12 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 45

TABLE 13 GLOBAL MENIERE’S DISEASE TREATMENT MARKET FOR HOSPITAL AND CLINICS, BY REGION, 2022–2030 (USD Billion) 46

TABLE 14 GLOBAL MENIERE’S DISEASE TREATMENT MARKET FOR SPECIALTY CENTERS, BY REGION, 2022–2030 (USD Billion) 47

TABLE 15 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, BY REGION, 2022–2030 (USD Billion) 49

TABLE 16 AMERICAS: MENIERE’S DISEASE TREATMENT MARKET, BY REGION, 2022–2030 (USD Billion) 51

TABLE 17 AMERICAS: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 51

TABLE 18 AMERICAS: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 52

TABLE 19 AMERICAS: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 52

TABLE 20 AMERICAS: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 53

TABLE 21 AMERICAS: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 53

TABLE 22 AMERICAS: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 54

TABLE 23 NORTH AMERICA: MENIERE’S DISEASE TREATMENT MARKET, BY COUNTRY, 2022–2030 (USD Billion) 55

TABLE 24 NORTH AMERICA: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 55

TABLE 25 NORTH AMERICA: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 56

TABLE 26 NORTH AMERICA: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 56

TABLE 27 NORTH AMERICA: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 57

TABLE 28 NORTH AMERICA: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 57

TABLE 29 NORTH AMERICA: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 58

TABLE 30 US: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 58

TABLE 31 US: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 59

TABLE 32 US: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 59

TABLE 33 US: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 60

TABLE 34 US: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 60

TABLE 35 US: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 61

TABLE 36 CANADA: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 61

TABLE 37 CANADA: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 62

TABLE 38 CANADA: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 62

TABLE 39 CANADA: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 63

TABLE 40 CANADA: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 63

TABLE 41 CANADA: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 64

TABLE 42 LATIN AMERICA: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 64

TABLE 43 LATIN AMERICA: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 65

TABLE 44 LATIN AMERICA: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 65

TABLE 45 LATIN AMERICA: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 66

TABLE 46 LATIN AMERICA: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 66

TABLE 47 LATIN AMERICA: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 67

TABLE 48 EUROPE: MENIERE’S DISEASE TREATMENT MARKET, BY REGION, 2022–2030 (USD Billion) 69

TABLE 49 EUROPE: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 69

TABLE 50 EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 70

TABLE 51 EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 70

TABLE 52 EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 71

TABLE 53 EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 71

TABLE 54 EUROPE: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 72

TABLE 55 WESTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, BY COUNTRY, 2022–2030 (USD Billion) 73

TABLE 56 WESTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 73

TABLE 57 WESTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 74

TABLE 58 WESTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 74

TABLE 59 WESTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 75

TABLE 60 WESTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 75

TABLE 61 WESTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 76

TABLE 62 GERMANY: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 76

TABLE 63 GERMANY: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 77

TABLE 64 GERMANY: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 77

TABLE 65 GERMANY: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 78

TABLE 66 GERMANY: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 78

TABLE 67 GERMANY: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 79

TABLE 68 UK: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 79

TABLE 69 UK: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 80

TABLE 70 UK: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 80

TABLE 71 UK: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 81

TABLE 72 UK: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 81

TABLE 73 UK: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 82

TABLE 74 FRANCE: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 82

TABLE 75 FRANCE: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 83

TABLE 76 FRANCE: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 83

TABLE 77 FRANCE: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 84

TABLE 78 FRANCE: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 84

TABLE 79 FRANCE: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 85

TABLE 80 ITALY: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 85

TABLE 81 ITALY: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 86

TABLE 82 ITALY: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 86

TABLE 83 ITALY: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 87

TABLE 84 ITALY: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 87

TABLE 85 ITALY: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 88

TABLE 86 SPAIN: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 88

TABLE 87 SPAIN: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 89

TABLE 88 SPAIN: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 89

TABLE 89 SPAIN: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 90

TABLE 90 SPAIN: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 90

TABLE 91 SPAIN: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 91

TABLE 92 REST OF WESTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 91

TABLE 93 REST OF WESTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 92

TABLE 94 REST OF WESTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 92

TABLE 95 REST OF WESTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 93

TABLE 96 REST OF WESTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 93

TABLE 97 REST OF WESTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 94

TABLE 98 EASTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 94

TABLE 99 EASTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 95

TABLE 100 EASTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 95

TABLE 101 EASTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 96

TABLE 102 EASTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 96

TABLE 103 EASTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 97

TABLE 104 ASIA-PACIFIC: MENIERE’S DISEASE TREATMENT MARKET, BY COUNTRY, 2022–2030 (USD Billion) 99

TABLE 105 ASIA-PACIFIC: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 99

TABLE 106 ASIA-PACIFIC: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 100

TABLE 107 ASIA-PACIFIC: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 100

TABLE 108 ASIA-PACIFIC: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 101

TABLE 109 ASIA-PACIFIC: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 101

TABLE 110 ASIA-PACIFIC: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 102

TABLE 111 JAPAN: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 102

TABLE 112 JAPAN: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 103

TABLE 113 JAPAN: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 103

TABLE 114 JAPAN: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 104

TABLE 115 JAPAN: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 104

TABLE 116 JAPAN: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 105

TABLE 117 AUSTRALIA: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 105

TABLE 118 AUSTRALIA: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 106

TABLE 119 AUSTRALIA: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 106

TABLE 120 AUSTRALIA: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 107

TABLE 121 AUSTRALIA: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 107

TABLE 122 AUSTRALIA: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 108

TABLE 123 CHINA: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 108

TABLE 124 CHINA: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 109

TABLE 125 CHINA: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 109

TABLE 126 CHINA: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 110

TABLE 127 CHINA: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 110

TABLE 128 CHINA: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 111

TABLE 129 INDIA: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 111

TABLE 130 INDIA: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 112

TABLE 131 INDIA: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 112

TABLE 132 INDIA: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 113

TABLE 133 INDIA: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 113

TABLE 134 INDIA: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 114

TABLE 135 SOUTH KOREA: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 114

TABLE 136 SOUTH KOREA: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 115

TABLE 137 SOUTH KOREA: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 115

TABLE 138 SOUTH KOREA: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 116

TABLE 139 SOUTH KOREA: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 116

TABLE 140 SOUTH KOREA: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 117

TABLE 141 REST OF ASIA-PACIFIC: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 117

TABLE 142 REST OF ASIA-PACIFIC: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 118

TABLE 143 REST OF ASIA-PACIFIC: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 118

TABLE 144 REST OF ASIA-PACIFIC: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 119

TABLE 145 REST OF ASIA-PACIFIC: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 119

TABLE 146 REST OF ASIA-PACIFIC: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 120

TABLE 147 MIDDLE EAST & AFRICA: MENIERE’S DISEASE TREATMENT MARKET, BY REGION, 2022–2030 (USD Billion) 122

TABLE 148 MIDDLE EAST & AFRICA: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 122

TABLE 149 MIDDLE EAST & AFRICA: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 123

TABLE 150 MIDDLE EAST & AFRICA: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 123

TABLE 151 MIDDLE EAST & AFRICA: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 124

TABLE 152 MIDDLE EAST & AFRICA: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 124

TABLE 153 MIDDLE EAST & AFRICA: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 125

TABLE 154 MIDDLE EAST: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 125

TABLE 155 MIDDLE EAST: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 126

TABLE 156 MIDDLE EAST: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 126

TABLE 157 MIDDLE EAST: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 127

TABLE 158 MIDDLE EAST: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 127

TABLE 159 MIDDLE EAST: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 128

TABLE 160 AFRICA: MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion) 128

TABLE 161 AFRICA: MENIERE’S DISEASE TREATMENT MARKET, FOR DRUGS, BY TYPE, 2022–2030 (USD Billion) 129

TABLE 162 AFRICA: MENIERE’S DISEASE TREATMENT MARKET, FOR ANTI-VERTIGO DRUGS, BY DRUG TYPE, 2022–2030 (USD Billion) 129

TABLE 163 AFRICA: MENIERE’S DISEASE TREATMENT MARKET, FOR INJECTIONS, BY TYPE, 2022–2030 (USD Billion) 130

TABLE 164 AFRICA: MENIERE’S DISEASE TREATMENT MARKET, FOR SURGERY, BY TYPE, 2022–2030 (USD Billion) 130

TABLE 165 AFRICA: MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion) 131

TABLE 166 LINA MEDICAL APS: PRODUCTS/SERVICES OFFERED 136

TABLE 167 WALLACE PHARMA: PRODUCTS/SERVICES OFFERED 138

TABLE 168 JUBILANT CADISTA: PRODUCTS/SERVICES OFFERED 141

TABLE 169 PFIZER INC.: PRODUCTS/SERVICES OFFERED 144

TABLE 170 GLENMARK PHARMACEUTICALS: PRODUCTS/SERVICES OFFERED 147

TABLE 171 GLAXOSMITHKLINE PLC: PRODUCTS/SERVICES OFFERED 150

TABLE 172 WELLSPRING PHARMACEUTICAL CORPORATION: PRODUCTS/SERVICES OFFERED 152

TABLE 173 SOUND PHARMACEUTICALS: PRODUCTS/SERVICES OFFERED 154

TABLE 174 AURIS MEDICAL: PRODUCTS/SERVICES OFFERED 156

TABLE 175 AURIS MEDICAL: KEY DEVELOPMENTS 156

TABLE 176 OTONOMY, INC.: PRODUCTS/SERVICES OFFERED 159

TABLE 177 OTONOMY, INC.: KEY DEVELOPMENTS 159

13 LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 15

FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS (2022) 16

FIGURE 3 GLOBAL MENIERE’S DISEASE TREATMENT MARKET ANALYSIS, BY TREATMENT 17

FIGURE 4 GLOBAL MENIERE’S DISEASE TREATMENT MARKET ANALYSIS, BY END USER 18

FIGURE 5 GLOBAL MENIERE’S DISEASE TREATMENT MARKET: STRUCTURE 20

FIGURE 6 BOTTOM-UP AND TOP-DOWN APPROACHES 26

FIGURE 7 PORTER’S FIVE FORCES ANALYSIS: GLOBAL MENIERE’S DISEASE TREATMENT MARKET 28

FIGURE 8 VALUE CHAIN ANALYSIS OF THE GLOBAL MENIERE’S DISEASE TREATMENT MARKET 30

FIGURE 9 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL MENIERE’S DISEASE TREATMENT MARKET 32

FIGURE 10 GLOBAL MENIERE’S DISEASE TREATMENT MARKET SHARE, BY TREATMENT, 2022 (%) 36

FIGURE 11 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, BY TREATMENT, 2022 AND 2030 (USD Billion) 37

FIGURE 12 GLOBAL MENIERE’S DISEASE TREATMENT MARKET SHARE, BY END USER, 2022 (%) 44

FIGURE 13 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, BY END USER, 2022 AND 2030 (USD Billion) 45

FIGURE 14 GLOBAL MENIERE’S DISEASE TREATMENT MARKET SHARE, BY REGION, 2022 (%) 48

FIGURE 15 GLOBAL MENIERE’S DISEASE TREATMENT MARKET, BY REGION, 2022 AND 2030 (USD Billion) 49

FIGURE 16 AMERICAS: MENIERE’S DISEASE TREATMENT MARKET, BY REGION 50

FIGURE 17 NORTH AMERICA: MENIERE’S DISEASE TREATMENT MARKET, BY COUNTRY 54

FIGURE 18 EUROPE: MENIERE’S DISEASE TREATMENT MARKET, BY REGION 68

FIGURE 19 WESTERN EUROPE: MENIERE’S DISEASE TREATMENT MARKET, BY COUNTRY 72

FIGURE 20 ASIA-PACIFIC: MENIERE’S DISEASE TREATMENT MARKET, BY COUNTRY 98

FIGURE 21 MIDDLE EAST & AFRICA: MENIERE’S DISEASE TREATMENT MARKET, BY REGION 121

FIGURE 22 BENCHMARKING OF MAJOR COMPETITORS 133

FIGURE 23 COMPETITOR DASHBOARD: GLOBAL MENIERE’S DISEASE TREATMENT MARKET 134

FIGURE 24 LINA MEDICAL APS: SWOT ANALYSIS 137

FIGURE 25 WALLACE PHARMA: SWOT ANALYSIS 139

FIGURE 26 JUBILANT CADISTA: FINANCIAL OVERVIEW SNAPSHOT 141

FIGURE 27 JUBILANT CADISTA: SWOT ANALYSIS 142

FIGURE 28 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 144

FIGURE 29 PFIZER INC.: SWOT ANALYSIS 145

FIGURE 30 GLENMARK PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT 147

FIGURE 31 GLENMARK PHARMACEUTICALS: SWOT ANALYSIS 148

FIGURE 32 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 150

FIGURE 33 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 151

FIGURE 34 WELLSPRING PHARMACEUTICAL CORPORATION: SWOT ANALYSIS 153

FIGURE 35 SOUND PHARMACEUTICALS: SWOT ANALYSIS 155

FIGURE 36 AURIS MEDICAL: SWOT ANALYSIS 157

FIGURE 37 OTONOMY, INC.: FINANCIAL OVERVIEW 158

FIGURE 38 OTONOMY, INC.: SWOT ANALYSIS 160